Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$201.06
-0.8%
$213.18
$176.57
$244.81
$355.79B0.327.08 million shs225,992 shs
Astrazeneca Plc stock logo
AZN
Astrazeneca
$182.06
-0.3%
$194.66
$132.32
$212.71
$282.57B0.262.71 million shs97,872 shs
GSK PLC Sponsored ADR stock logo
GSK
GSK
$50.17
-0.7%
$55.25
$35.45
$61.69
$101.98B0.385.10 million shs143,812 shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$957.96
-1.7%
$943.90
$623.78
$1,133.95
$905.21B0.483.17 million shs139,965 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
-1.24%-4.29%-1.75%-9.36%+7.83%
Astrazeneca Plc stock logo
AZN
Astrazeneca
-1.24%-2.63%-8.99%-5.37%+30.35%
GSK PLC Sponsored ADR stock logo
GSK
GSK
-0.17%-3.65%-9.51%-16.05%+36.04%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-1.29%+4.03%+4.81%-7.78%+25.47%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$201.06
-0.8%
$213.18
$176.57
$244.81
$355.79B0.327.08 million shs225,992 shs
Astrazeneca Plc stock logo
AZN
Astrazeneca
$182.06
-0.3%
$194.66
$132.32
$212.71
$282.57B0.262.71 million shs97,872 shs
GSK PLC Sponsored ADR stock logo
GSK
GSK
$50.17
-0.7%
$55.25
$35.45
$61.69
$101.98B0.385.10 million shs143,812 shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$957.96
-1.7%
$943.90
$623.78
$1,133.95
$905.21B0.483.17 million shs139,965 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
-1.24%-4.29%-1.75%-9.36%+7.83%
Astrazeneca Plc stock logo
AZN
Astrazeneca
-1.24%-2.63%-8.99%-5.37%+30.35%
GSK PLC Sponsored ADR stock logo
GSK
GSK
-0.17%-3.65%-9.51%-16.05%+36.04%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-1.29%+4.03%+4.81%-7.78%+25.47%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbbVie Inc. stock logo
ABBV
AbbVie
2.88
Moderate Buy$252.9025.79% Upside
Astrazeneca Plc stock logo
AZN
Astrazeneca
2.85
Moderate Buy$205.3312.78% Upside
GSK PLC Sponsored ADR stock logo
GSK
GSK
1.90
Reduce$53.005.64% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.87
Moderate Buy$1,218.3327.18% Upside

Current Analyst Ratings Breakdown

Latest AZN, LLY, ABBV, and GSK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/7/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price Target$880.00 ➝ $900.00
5/5/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingBuy$1,183.00
5/4/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
UpgradeBuy (B-)Buy (B)
5/4/2026
Astrazeneca Plc stock logo
AZN
Astrazeneca
Reiterated RatingBuy
5/4/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingOutperform$1,325.00
5/4/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetOverweight$1,350.00 ➝ $1,400.00
5/1/2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
UpgradeHold (C+)Buy (B)
5/1/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingOverweight$1,344.00
5/1/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Reiterated RatingBuy$249.00
5/1/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingOutperform
5/1/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Lower Price TargetBuy$1,294.00 ➝ $1,133.00
(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbbVie Inc. stock logo
ABBV
AbbVie
$62.82B5.66$14.85 per share13.54($1.83) per share-109.87
Astrazeneca Plc stock logo
AZN
Astrazeneca
$58.74B4.81$12.73 per share14.30$30.55 per share5.96
GSK PLC Sponsored ADR stock logo
GSK
GSK
$32.78B3.11$5.97 per share8.41$11.57 per share4.34
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$65.18B13.84$24.40 per share39.26$33.13 per share28.92
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbbVie Inc. stock logo
ABBV
AbbVie
$4.23B$2.0399.1212.370.715.79%-911.57%13.43%N/A
Astrazeneca Plc stock logo
AZN
Astrazeneca
$10.23B$6.6627.3615.821.5217.19%30.86%12.68%7/27/2026 (Estimated)
GSK PLC Sponsored ADR stock logo
GSK
GSK
$7.54B$3.8513.069.782.5617.82%44.28%11.49%N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$20.64B$28.1534.1522.091.0834.98%105.77%23.76%N/A

Latest AZN, LLY, ABBV, and GSK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/30/2026Q1 2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.97$8.55+$1.58$8.26$17.82 billion$19.80 billion
4/29/2026Q1 2026
AbbVie Inc. stock logo
ABBV
AbbVie
$2.59$2.65+$0.06$0.39$14.72 billion$15.00 billion
4/29/2026Q1 2026
Astrazeneca Plc stock logo
AZN
Astrazeneca
$2.52$2.58+$0.06$0.9850$14.93 billion$15.29 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AbbVie Inc. stock logo
ABBV
AbbVie
$6.923.44%+6.80%340.89%53 Years
Astrazeneca Plc stock logo
AZN
Astrazeneca
$4.342.38%+2.30%65.17%N/A
GSK PLC Sponsored ADR stock logo
GSK
GSK
$1.563.11%-7.86%40.52%N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.920.72%+15.18%24.58%11 Years

Latest AZN, LLY, ABBV, and GSK Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/29/2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
quarterly$0.443.36%5/15/20265/15/20267/9/2026
5/4/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.730.72%5/15/20265/15/20266/10/2026
2/19/2026
AbbVie Inc. stock logo
ABBV
AbbVie
quarterly$1.733.32%4/15/20264/15/20265/15/2026
2/10/2026
Astrazeneca Plc stock logo
AZN
Astrazeneca
$1.59501.56%2/20/20262/20/20263/23/2026
1/1/2100
GSK PLC Sponsored ADR stock logo
GSK
GSK
quarterly$0.42064.3%8/15/20258/15/202510/9/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbbVie Inc. stock logo
ABBV
AbbVie
N/A
0.67
0.56
Astrazeneca Plc stock logo
AZN
Astrazeneca
0.52
0.91
0.71
GSK PLC Sponsored ADR stock logo
GSK
GSK
0.80
0.79
0.52
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.26
1.50
1.10

Institutional Ownership

CompanyInstitutional Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
70.23%
Astrazeneca Plc stock logo
AZN
Astrazeneca
20.35%
GSK PLC Sponsored ADR stock logo
GSK
GSK
15.74%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%

Insider Ownership

CompanyInsider Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
0.06%
Astrazeneca Plc stock logo
AZN
Astrazeneca
N/A
GSK PLC Sponsored ADR stock logo
GSK
GSK
10.00%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.14%
CompanyEmployeesShares OutstandingFree FloatOptionable
AbbVie Inc. stock logo
ABBV
AbbVie
57,0001.77 billion1.77 billionOptionable
Astrazeneca Plc stock logo
AZN
Astrazeneca
96,1001.55 billionN/AN/A
GSK PLC Sponsored ADR stock logo
GSK
GSK
66,8412.03 billion1.83 billionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
50,000941.74 million940.42 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
AbbVie stock logo

AbbVie NYSE:ABBV

$201.06 -1.65 (-0.81%)
As of 10:00 AM Eastern
This is a fair market value price provided by Massive. Learn more.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Astrazeneca stock logo

Astrazeneca NYSE:AZN

$182.06 -0.46 (-0.25%)
As of 10:00 AM Eastern
This is a fair market value price provided by Massive. Learn more.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

GSK stock logo

GSK NYSE:GSK

$50.17 -0.33 (-0.65%)
As of 10:00 AM Eastern
This is a fair market value price provided by Massive. Learn more.

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$957.96 -17.00 (-1.74%)
As of 10:00 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.